Trial
NCT00568633
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Stanford University
Collaborators
Genzyme, a Sanofi Company
Condition
Leukemia, Myeloid
Intervention
Allogeneic HSCT
Why stopped
Poor accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-09-24